States, Bayer settle case alleging deceptive advertising
Pharma Compliance Alert, February 11, 2009
Bayer entered into a settlement with 27 states to resolve allegations it deceptively marketed its oral contraceptive Yaz, according to a press release from Massachusetts Attorney General Martha Coakley.
In 2007, Bayer reached an agreement to resolve allegations of deceptive advertising of products, including non-disclosure of safety risks associated with its marketing of Baycol. The 2008 settlement resolves allegations that Bayer violated the terms of the 2007 agreement by not disclosing the FDA approved uses of Yaz.
Read more about Bayer's settlement for alleged deceptive advertising.
Related Products
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- Q/A: Coding for telescopic intraocular lens
- New FAQ posted on storing laryngoscope blades
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- "Wall fountains" may be spreading Legionnaires to patients, visitors
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- COT basics to best
- Searched
